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Abstract: Acetylcholine-induced vasorelaxation (AChIR) and responses to reduced pO2 (hypoxia-
induced relaxation (HIR), 0% O2) were assessed in vitro in aortic rings of healthy male Sprague-
Dawley rats (N = 252) under hyperbaric (HBO2) protocols. The studied groups consisted of the CTRL 
group (untreated); the A-HBO2 group (single HBO2; 120 min of 100% O2 at 2.0 bars); the 24H-HBO2 
group (examined 24 h after single exposure) and the 4D-HBO2 group (four consecutive days of 
single HBO2). AChIR, sensitivity to ACh and iNOS expression were decreased in the A-HBO2 group. 
HIR was prostanoid- and epoxyeicosatrienoic acid (EET)-mediated. HIF-1α expression was 
increased in the 24H-HBO2 and 4D-HBO2 groups. LW6 (HIF-1α inhibitor) decreased HIR in the 24H-
HBO2 group. HBO2 affected the expression of COX-1 and COX-2. CYP2c11 expression was elevated 
in the 24H-HBO2 and 4D-HBO2 groups. Concentrations of arachidonic acid (AA) metabolites 14(15)-
DiHET, 11(12)-DiHET and 8(9)-DiHET were increased in A-HBO2 and 24H-HBO2. An increased 
concentration of 8(9)-EET was observed in the A-HBO2 and 24h-HBO2 groups vs. the CTRL and 4D-
HBO2 groups, and an increased concentration of 5(6)-DiHET was observed in the 24H-HBO2 group 
vs. the 4D-HBO2 group. The 20-HETE concentration was increased in the A-HBO2 group. All were 
determined by LC-MS/MS of the aorta. The results show that AChIR in all groups is mostly NO-
dependent. HIR is undoubtedly mediated by the CYP450 enzymes’ metabolites of AA, whereas HIF-
1α contributes to restored HIR. Vasoconstrictor metabolites of CYP450 enzymes contribute to 
attenuated AChIR and HIR in A-HBO2. 
Keywords: acetylcholine; aortic rings; epoxyeicosatrienoic acids; hyperbaric oxygenation; hypoxia; 
HIF-1α 
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1. Introduction 
Although the beneficial effects of hyperbaric oxygenation (HBO2) on tissue perfusion are well 
documented, there is a paucity of knowledge about the mechanisms by which HBO2 improves tissue 
oxygenation. It is known that various arachidonic acid metabolites (prostaglandins, 
epoxyeicosatrienoic acids (EETs), hydroxy-eicosatrienoic acids (HETEs)) and NO are of the utmost 
importance in mediating vascular reactivity to vasodilators and vasoconstrictors [1–5], including 
hypoxia and hyperoxia stimuli [6]. In conditions of reduced blood flow, the use of HBO2 can 
significantly increase tissue oxygenation. Intermittent exposure to HBO2 has been shown to cause 
activation of the CYP450 epoxygenase pathway in the macrovasculature of diabetic animals and to 
restore vasorelaxation of aortic rings in response to acetylcholine [7]. Furthermore, Kibel et al. (2012; 
2015) showed an improved relaxation response to ANGII and ANG- (1–7) in healthy animals treated 
by intermittent HBO2 due to activation of mechanisms related to CYP450 enzyme activation and EET 
synthesis [8,9]. However, the way in which acute or intermittent HBO2 affects the mechanisms of 
vasodilation to physiological stimuli such as reduced pO2 or acetylcholine (ACh) in healthy blood 
vessels is still not known. Since HBO2 has been increasingly used both for health (e.g., sport) 
treatments and cosmetic purposes, understanding the mechanisms of action and consequences of the 
utilization of HBO2 in healthy individuals is of primary importance. 
Endothelial cells metabolize arachidonic acid (AA) via CYP450 enzymes (ω-hydroxylase and 
epoxygenase), via cyclooxygenases and 5-lipooxygenase, and by non-enzymatic degradation of 
arachidonic acid in the presence of free radicals [10]. Epoxygenases are members of cytochrome P450 
family of enzymes, which in the endothelial cell produce four epoxyeicosatrienoic acid (EET) isomers, 
of which 14,15-EET and 11,12-EET are the major active vasodilator metabolites [10–15]. ω-
hydroxylase, in smooth muscle cells, promotes the production of 20-hydroxy-eicosatrienoic acid (20-
HETE), which is a vasoconstrictor [15,16]. Two isoforms of cyclooxygenase (COX-1 and COX-2) are 
involved in the synthesis of prostanoids from AA. The resulting prostanoids act antagonistically, 
causing vasodilation (prostaglandin D2, prostaglandin E2 and prostacyclin I2) and vasoconstriction 
(prostaglandin F2α and thromboxane A2). Hypoxia activates COX-1 to produce prostacyclin (PGI2), 
which promotes the opening of several types of potassium channels via cAMP, resulting in 
hyperpolarization of the smooth muscle membrane and consequent vasodilation [10]. Increased 
oxygen delivery significantly activates CYP450 enzymes and increases the production of 20-HETE, 
and also EET [17]. 
Recently, we showed that increased superoxide production and an overall increase in oxidative 
stress impairs vasorelaxation in rats acutely exposed to HBO2, whereas intermittent exposure to HBO2 
increases the expression and activity of antioxidative enzymes, suggesting that intermittent HBO2 
induces antioxidative defense mechanisms underlying restored vasorelaxation [18]. Altogether, there 
is no clear answer as to which mediators are involved in the vasoconstriction or vasorelaxation 
observed in various HBO2 protocols, because up to the present study, no measurements of vascular 
eicosanoids production have yet been performed. 
The role of transcription factor hypoxia inducible factor 1 alpha (HIF-1α) in the effects of HBO2 
was described in studies on wound healing (diabetic foot, postiradiation injury). HIF-1α is involved 
in neovascularization, cell proliferation and increased mobilization of progenitor endothelial cells 
from bone marrow [19,20]. HBO2 activates HIF-1α at several levels by increasing both HIF-1α stability 
and activity [21]. Hypoxia and reactive oxygen species (ROS)/ reactive nitrogen species (RNS) may 
stimulate HIF-1α stabilization, leading to the activation of hypoxia-induced cellular signaling 
pathways [22]. There is a limited knowledge on the role of HIF-1α on vascular reactivity in conditions 
of elevated oxidative stress and exposure to HBO2. 
Taken together, the hypothesis of the present study was that HBO2 changes the mechanisms of 
vascular relaxation and affects HIF-1α expression. Furthermore, HIF-1α is involved in vascular 
relaxation mechanisms, depending on the duration and frequency of HBO2 exposure. Therefore, the 
purpose of this study was to investigate whether the mechanisms of ACh- and hypoxia-induced 
vascular relaxation in healthy rats and the expression of HIF-1α in aortic tissue were influenced by 
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acute and intermittent HBO2. A further goal was to determine the involvement of metabolites of AA, 
produced in CYP450 enzymatic pathways, in vasorelaxation in different HBO2 protocols. 
2. Results 
2.1. Body Mass and Blood Pressure of Studied Groups 
Body mass (g) of rats was not significantly different among examined groups. There was a 
significant decrease in mean arterial pressure in the A-HBO2 group, compared to other groups (Table 
1). 
Table 1. Measurements of body mass and mean arterial pressure. 
 CTRL A-HBO2 24H-HBO2 4D-HBO2 
Body mass [g] 329.4 ± 18.25 332.4 ± 21.53 318.6 ± 29.62 323.20 ± 39.49 
Mean arterial pressure [mmHg] 107 ± 4 82 ± 5 * 107 ± 9 105 ± 3 
*Results are shown as mean ± SD (standard deviation); n = 6 (number of rats per group), * p < 0.05 
compared to CTRL group. CTRL–untreated group; A-HBO2–group receiving a single HBO2 exposure; 
24H-HBO2–group examined 24 h after single exposure; 4D-HBO2–group receiving four consecutive 
days of single HBO2 exposure. 
2.2. Acetylcholine-Induced Vasorelaxation (AChIR) of Isolated Rat Aortic Rings 
Figure 1a presents the results of isolated aortic ring baseline vasorelaxation in response to ACh 
(AChIR) in all experimental groups of rats. AChIR was significantly reduced in the A-HBO2 group 
(the group receiving a single HBO2 exposure) compared to all other groups of animals. A-HBO2 rats 
also exhibited lower sensitivity to ACh compared to other groups of rats (presented by logEC50 in 
tables). HBO2 significantly affected AChIR by reducing the inhibition of vasorelaxation caused by L-
NAME compared to the control (CTRL) group, although sensitivity to ACh was not significantly 
different (Figure 1b). 
The role of COX-1 and COX-2 metabolites was assessed with indomethacin. In the 4D-HBO2 
group (receiving four consecutive days of single HBO2 exposure), AChIR was significantly improved 
after indomethacin compared to the other groups. In the 24H-HBO2 group (examined 24 h after single 
exposure) indomethacin partially inhibited AChIR at a dose of 10−7 mol L−1 compared to the CTRL 
group (Figure 1c). Furthermore, MS-PPOH, an inhibitor of epoxygenase reactions significantly 
inhibited AChIR in the A-HBO2 group compared to the CTRL and 24H-HBO2 groups at ACh 
concentrations of 10−9–10−7 mol L−1, and compared to the 4D-HBO2 group at 10−7 mol L−1. MS-PPOH 
partially inhibited AChIR at 10−8 mol L−1 in the 4D-HBO2 group versus the CTRL group (Figure 1d). 
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Figure 1. Ach-induced relaxation (AChIR) of isolated rat aorta rings in the CTRL, A-HBO2, 24H-HBO2 
and 4D-HBO2 groups. Baseline relaxation to acetylcholine (a) and relaxation to acetylcholine in the 
presence of eNOS inhibitor L-NAME (b), COX inhibitor INDO (c) and a selective CYP450 epoxidase 
inhibitor, MS-PPOH (d) in CTRL, A-HBO2, 24H-HBO2 and 4D-HBO2 groups of rats. Results are 
presented as mean ± SD; N – number of aortic rings; p < 0.05. 
Figure 2 presents the mechanisms of AChIR in each experimental group of rats. Administration 
of L-NAME eliminated AChIR in the CTRL, A-HBO2 and 24H-HBO2 groups. In the 4D-HBO2 group, 
the AChIR of the aortic rings was partially inhibited by the use of L-NAME and partially inhibited 
by MS-PPOH at ACh doses of 10−6 mol L−1 and 10−7 mol L−1 (Figure 2d). 
The sensitivity to ACh (presented by logEC50 in the tables) decreased with L-NAME in the 
CTRL group. In the A-HBO2 group (Figure 2b), indomethacin increased the sensitivity of aortic rings 
to ACh, whereas L-NAME and MS-PPOH decreased the sensitivity to ACh compared to the baseline 
response. In the 24H-HBO2 group (Figure 2c), ACh sensitivity was mostly reduced by L-NAME 
compared to the baseline response. MS-PPOH and indomethacin also reduced the sensitivity to ACh 
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compared to the CTRL group. In the 4D-HBO2 group, ACh sensitivity was also decreased in the 
presence of L-NAME, and increased in the presence of indomethacin and MS-PPOH (Figure 2d). 
 
Figure 2. Mechanisms of AChIR response of isolated rat aorta rings in CTRL (a), A-HBO2 (b), 24H-
HBO2 (c) and 4D-HBO2 (d) groups of rats with and without inhibitors (L-NAME, INDO, MS-PPOH). 
Results are presented as mean ± SD; N – number of aortic rings; p < 0.05. 
2.3. Hypoxia-Induced Vasorelaxation of Isolated Rat Aortic Rings 
The A-HBO2 group exhibited significantly decreased baseline vasorelaxation in response to 
hypoxia (hypoxia-induced relaxation (HIR)) compared to all other groups of rats. The 24H-HBO2 and 
4D-HBO2 groups exhibited significantly enhanced HIR compared to the CTRL and A-HBO2 groups 
of rats (Figure 3a). HIR was significantly lower in the presence of INDO, MS-PPOH and INDO + MS-
PPOH compared to the baseline in the CTRL and 4D-HBO2 groups (Figure 3b,e). INDO eliminated 
HIR in A-HBO2, whereas MS-PPOH and HIF-1α inhibitor did not have a significant effect in that 
group (Figure 3c). The combination of INDO and MS-PPOH significantly reduced the relaxation in 
the A-HBO2 group compared to the baseline, similar to that of INDO per se. In the 24h-HBO2 group 
(Figure 3d) significant inhibition of HIR was achieved in the presence of INDO and MS-PPOH 
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individually, in the presence of both INDO + MS − PPOH and in the presence of LW6 (HIF-1α 
inhibitor) compared to the baseline response. The use of L-NAME had no effect on the relaxation 
response to hypoxia in any of tested groups (Figure 3b–e). 
 
Figure 3. Hypoxia-induced relaxation (HIR) response of isolated rat aorta rings in CTRL (b), A-HBO2 
(c), 24H-HBO2 (d) and 4D-HBO2 (e) groups without (a) and with inhibitors L-NAME, INDO, MS-
PPOH, INDO + MS − PPOH and HIF-1α inhibitor – LW6. Results are presented as mean ± SD; n – 
number of rats, N – number of aortic rings; * p < 0.05 compared to baseline. 
2.4. Relative mRNA and Protein Expression of Enzymes in Rat Aorta 
Relative mRNA expression of COX-1 was significantly reduced only in the 24H-HBO2 group, 
compared to other groups (Table 2, Figure 4). mRNA expression of COX-2 was significantly reduced 
in the 4D-HBO2 group, whereas protein expression of COX-2 was significantly increased compared 
to controls (Table 2, Figure 5b). COX-2 mRNA was also significantly reduced in the 24H-HBO2 and 
4D-HBO2 groups, compared to the A-HBO2 group. The relative mRNA expression of iNOS was 
significantly reduced in the A-HBO2 and 24H-HBO2 groups, compared to the control group, whereas 
eNOS expression was not significantly different among the groups (Table 2, Figure 4). 
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Table 2. Relative mRNA expression of cyclooxygenase 1 and 2 (COX 1 and COX 2), nitric oxide 
synthase (iNOS and eNOS), hypoxia inducible factor 1 alpha (HIF-1α), vascular endothelial growth 
factor (VEGF) and CYP2C11 in rat aorta normalized to HPRT housekeeping gene. 
 CTRL A-HBO2 24H-HBO2 4D-HBO2 
COX-1 4.20 ± 1.49 4.42 ± 1.87 1.74 ± 0.59 *†‡ 3.53 ± 0.88 
COX-2 1.18 ± 0.78 1.45 ± 0.88 0.47 ± 0.33 † 0.33 ± 0.37 *† 
eNOS 0.13 ± 0.12 0.03 ± 0.03 0.13 ± 0.13 0.04 ± 0.03 
iNOS 0.38 ± 0.21 0.11 ± 0.04* 0.12 ± 0.08 * 0.21 ± 0.11 
HIF-1α 0.38 ± 0.31 0.48 ± 0.33 0.82 ± 0.28 *† 0.75 ± 0.18 *† 
VEGF 0.19 ± 0.40 0.30 ± 0.26 0.53 ± 0.24 *† 0.58 ± 0.62 *† 
CYP2c11 1.11 ± 0.45 0.69 ± 0.26 0.55 ± 0.29 2.21 ± 1.09 *†‡ 
Data are presented as mean ± SD (standard deviation); n = 6 (number of rats per group). * p < 0.05 
compared to CTRL group; † p < 0.05 compared to A-HBO2 group; ‡p < 0.05 compared to 24H-HBO2 
group. 
 
Figure 4. Expressions of COX-1, COX-2, iNOS, eNOS, HIF-1α, VEGF and CYP2C11 in rat aorta in 
CTRL (a), A-HBO2 (b), 24H-HBO2 (c) and 4D-HBO2 group (d). Results were normalized to HPRT 
housekeeping gene and control and presented using whisker bars as fold change (2−ΔΔCT). * p < 0.05 
was considered significant. 
Relative expression of CYP2c11 mRNA was significantly elevated in the 4D-HBO2 group, 
compared to other groups (Table 2), whereas CYP2c11 protein expression was significantly increased 
in 24H-HBO2 and 4D-HBO2 compared to the CTRL group (Figure 5d). Other investigated proteins 
were similarly expressed among groups (Figure 5). 
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Figure 5. Relative protein expression and representative blots of (a) COX-1 – cyclooxygenase 1; (b) 
COX-2 – cyclooxygenase 2; (c) iNOS – inducible nitric oxide synthase; (d) CYP2C11; (e) HIF-1α and 
(f) VEGF in aortic tissue, determined by Western blot method. Results are shown as mean ± standard 
deviation (SD); * p < 0.05 compared to CTRL. 
2.5. HIF-1α mRNA and Protein Expression 
Relative gene expression of HIF-1α transcription factor and its target gene VEGF was 
significantly increased in the 24H-HBO2 and 4D-HBO2 groups, compared to the CTRL and A-HBO2 
groups (Table 2), fold change (2−ΔΔCT) didn’t showed significant changes (Figure 4). Relative protein 
expression of HIF-1α was significantly increased in 24H-HBO2 and 4D-HBO2, compared to the CTRL 
group (Figure 5e). 
2.6. Liquid Chromatography-Tandem Mass Spectrometry Determination of CYP450 Enzymatic Pathway 
Metabolites of Arachidonic Acid 
LC/MS-MS of metabolites of arachidonic acid, produced in CYP450 enzymatic pathways (Table 
3), in aorta samples showed significantly increased concentrations of vasodilatory EETs or their 
corresponding biodegradation products (DiHETs) as follows: increased concentrations of 14(15)-
DiHET, 11(12)-DiHET and 8(9)-DiHET in A-HBO2 and 24 h-HBO2 groups versus CTRL; increased 
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concentration of 8(9)-EET in A-HBO2 and 24 h-HBO2 groups vs. CTRL and 4D-HBO2 groups; and 
increased concentration of 5(6)-DiHET in 24h-HBO2 group vs. 4D-HBO2 group. 
Table 3. Liquid chromatography-tandem mass spectrometry (LC/MS–MS) determination of CYP450 
enzymatic pathway vasodilating 11(12)-epoxyeicosatrienoic acid (EET), 14(15)-EET, 8(9)-EET and 
corresponding DiHETs and vasoconstriction-causing metabolite (20- hydroxy-eicosatrienoic acid 
(HETE)) of arachidonic acid in aortic tissue. 
 CTRL A-HBO2 24H-HBO2 4D-HBO2 
AA-259 [μg g−1] 60.4 ± 20.39 48.7 ± 23.72 89.3 ± 34.19 † 45.4 ± 17.23 
11 (12)-EET [ng g−1] 0.57 ± 0.17 0.63 ± 0.26 0.46 ± 0.25 0.39 ± 0.16 
14 (15)-EET [ng g−1] 0.49 ± 0.11 0.49 ± 0.23 0.47 ± 0.26 0.35 ± 0.22 
20-HETE [ng g−1] 3.94 ± 1.59 6.43 ± 1.65 *† 4.64 ± 2.68 2.94 ± 1.51 
14 (15)-DiHET [ng g−1] 6.87 ± 0.92 9.84 ± 2.45 * 9.83 ± 2.11 * 7.51 ± 1.10 
11 (12)-DiHET [ng g−1] 2.62 ± 0.29 4.92 ± 1.74 * 4.13 ± 1.30 * 3.08 ± 0.53 
5 (6)-DiHET [ng g−1] 1.23 ± 0.41 1.12 ± 0.51 1.39 ± 0.23 † 1.08 ± 0.13 
8(9)-EET [ng g−1] 0.98 ± 0.17 1.41 ± 0.35 *† 1.50 ± 0.20 *† 0.88 ± 0.36 
8 (9)-DiHET [ng g−1] 1.67 ± 0.32 5.14 ± 0.94 * 4.75 ± 1.62 * 3.45 ± 1.77 
*Data are presented as mean ± SD (standard deviation); n = 5; * p < 0.05 compared to CTRL group; † p 
< 0.05 compared to 4D-HBO2 group. 
Determination of vasoconstrictory 20-HETE showed its increased concentration in the A-HBO2 
group compared to CTRL and 4D-HBO2 groups. There was a significantly decreased ratio of 14(15)-
EET to 20-HETE, 11(12)-DiHET to 20-HETE and 8(9)-EET to 20–HETE in the A-HBO2 group compared 
to other groups (CTRL, 24h-HBO2 and 4D-HBO2), and an increased ratio of 11(12)-DiHET to 20-HETE 
in the 4D-HBO2 group versus the CTRL and A-HBO2 groups (Table 4). 








11 (12)-DiHET/ 20HETE 
CTRL 0.158 ± 0.107 0.149 ± 0.078 0.317 ± 0.099 0.885 ± 0.391 
A-HBO2 0.098 ± 0.035 0.076 ± 0.033 *†‡ 0.173 ± 0.055 *†‡ 0.760 ± 0.179 *†‡ 
24H-HBO2 0.146 ± 0.084 0.131 ± 0.076 0.323 ± 0.173 1.228 ± 0.595 
4D-HBO2 0.166 ± 0.107 0.151 ± 0.095 0.312 ± 0.187 1.313 ± 0.758 * 
*Data are presented as mean ± SD (standard deviation); n = 5. * p < 0.05 compared to CTRL group; † p 
< 0.05 compared to 24h-HBO2 group; ‡ p < 0.05 compared to 4D-HBO2 group. 
3. Discussion 
The most important findings in the present study are: (a) a decrease in the contribution of NO 
to ACh-induced relaxation in HBO2-exposed animals; (b) improved hypoxia-stimulated relaxation 
after HBO2 (24 h after single exposure and intermittent HBO2); (c) for the first time, a demonstration 
that HBO2 may increase production of 20-HETE and EETs in aortic tissue and increase the ratio of 
vasodilatory/vasoconstrictor metabolites (after intermittent HBO2); (d) increased synthesis of HIF-1α 
and its involvement in hypoxia-stimulated relaxation of rat aortic rings, and (e) confirmation of EETs 
as endothelium-derived hyperpolarizing factors (EDHFs) and epoxygenases as oxygen sensors in 
HBO2. 
Recently, our research group [7–9] showed the engagement of alternative pathways of 
endothelium-dependent relaxation in response to acetylcholine and ANG (1–7) in diabetic animals 
exposed to four days of HBO2. Interestingly, some previous studies have shown that if HBO2 is 
applied more than once, adaptive mechanisms are activated to protect against further oxidative 
damage, e.g., increased antioxidative protection and general prevention against the genotoxic action 
of H2O2, mediated by increased protection by intracellular antioxidants of leukocytes and 
antioxidants, which scavenge ROS that are distant from nuclear DNA [23,24]. Consequently, HBO2 
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preconditioning can be used for the prevention of subsequent oxidative injuries [25,26]. These HBO2-
triggered adaptive and preconditional responses could also be responsible for changes in the 
underlying vascular reactivity mechanisms [7–9,27]. Since the effectiveness of HBO2 treatments 
generally depends on exposures being repeated within a few days [28], it is especially important to 
define HBO2’s molecular interactions when repeatedly applied. 
3.1. Body Mass and Blood Pressure of Studied Groups 
The observed decrease in mean arterial pressure is consistent with our previous studies, which 
discuss this issue [18,29]. Oxidative stress induced impaired baseline AChIR and HIR in the A-HBO2 
group, which was also previously described and discussed in our previous study [18]. 
3.2. The Mechanisms of Acetylcholine-induced Vasorelaxation  
The results show a decrease in the contribution of NO to ACh-induced relaxation in HBO2-
exposed animals, despite the increased sensitivity of vascular smooth muscles to NO, which appears 
to be proportional to the duration of HBO2 treatment (Figure 2b), as well as the equal contribution of 
COX-produced prostacyclin and CYP450 metabolites of AA in hypoxia-stimulated vascular 
relaxation (Figure 3). As mentioned above, our previous findings, presented by Unfirer et al. and 
Kibel et al. [7–9], also showed the presence of alternative pathways of endothelial relaxation to 
acetylcholine and ANG (1–7) in diabetic animals exposed to four days of HBO2, which represent the 
most likely avenues of increase in production or sensitivity to EETs. Most importantly, the discovery 
of the participation of CYP450 metabolites in vasorelaxation in HBO2 is a novelty of the present study. 
These metabolites have been measured here for the first time ever in aortic tissue after HBO2 
treatment. 
3.3. The Mechanisms of Hypoxia-induced Vasorelaxation  
A major part of the vasodilation response to hypoxia is mediated by the activation of COX and 
the consequent production of prostacyclin (PGI2), which then activates KATP channels [30]. Frisbee et 
al. [31] have shown that hypoxic vasodilation of skeletal muscular resistance arteries activates the 
cytochrome P450 enzyme pathway and that the hypoxic vasodilation response is not exclusively 
dependent on the COX pathway and prostacyclin production, but rather that EETs play a role in 
vasodilation in response to hypoxia. Some authors have shown that blood vessels with EDHF 
responses (coronary, cerebral and pulmonary) have a preserved EDHF response under severe 
hypoxia conditions, for which CYP450 epoxygenase is also responsible [32]. 
In the present study, the control group had an expected vasodilating response to hypoxia, 
whereas HIR was impaired after a single exposure to HBO2. Furthermore, 24h after HBO2 and after 
four days of repeated HBO2 treatments (i.e., intermittent exposures), an increased vasodilating 
response to hypoxia appeared, suggesting that HBO2 led to a change in the activation and/or 
expression of COX and/or CYP450 enzymes (Figure 3a). The vasodilation response of the control 
aorta was fully mediated by activation of COX and PGI2 formation, because vasodilation was almost 
completely blocked after incubation with indomethacin. MS-PPOH reduced vasodilation at half the 
value of the baseline, indicating that CYP450 epoxygenase and the formation of EETs play a smaller 
role in vasodilation in hypoxia (Figure 3b). Twenty-four hours after single exposure to HBO2 and 
after four consecutive days, incomplete inhibition of vasodilation occurs after the administration of 
indomethacin. There is an even greater inhibitory effect on vasodilation after the administration of 
MS-PPOH, indicating that HBO2 induced higher EET production. Overall, these functional results 
suggest an important switch from the production of COX metabolites to CYP450 vasodilator 
metabolites after intermittent HBO2 exposure. 
The particular significance of present work is that we have measured eicosanoid production in 
aortic tissue for the first time ever. These measurements (Tables 3 and 4) support the results of 
functional studies with inhibitors. Acute HBO2 exposure increased 20-HETE formation, which led to 
attenuated vasorelaxation in response to ACh and hypoxia. This explains the restored vasorelaxation 
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in 4D-HBO2 group and the altered mechanisms of vasorelaxation (with increased ratios of vasodilator 
to vasoconstrictor metabolites of CYP450 enzymes in this group), indicating that the vasodilation 
mechanisms are diverted to EETs. This is further supported by increased CYP2c11 gene and protein 
expression and an increased ratio of vasodilatory AA metabolites. Our results show increased 
concentrations of vasoconstrictor 20-HETE and a decreased ratio between various vasodilatory 
metabolites and 20-HETE in the A-HBO2 group, but also show increased concentrations of 
vasodilatory metabolites in the A-HBO2 and 24H-HBO2 groups. Altogether, our results confirm 
epoxygenase and omega-hydroxylase as oxygen sensors, and reveal for the first time that EETs are 
the mediators responsible for recovery of vasorelaxation after intermittent HBO2 treatment. 
Furthermore, the present study, with its direct measurements of CYP450 metabolites, confirms our 
hypothesis that periods between two hyperbaric exposures can be considered pseudohypoxia, which 
is a stimulus to enzyme upregulation and the alternation of vasoactive pathways [6,29]. The question 
of whether this is influenced by HIF-1α is discussed below. 
3.4. The Role of HIF-1α in Vasorelaxation in Response to ACh and Hypoxia 
Activation of HIF-1 involves redox-dependent stabilization of HIF-1α proteins [33]. In hypoxia, 
HIF-1α is translocated in the core and heterodimerized with a β subunit, forming the HIF-1 complex 
[34]. Two distinct domains within the HIF-1α subunit are responsive to cellular oxygen levels [35]. 
Expression and activation of the HIF-α subunits is firmly regulated, and their degradation by 
ubiquitin proteasome usually occurs in hyperoxic conditions [36,37]. However, independently of 
hypoxic or normoxic conditions, free radicals are needed to express HIF-α [36,37]. In acute HBO2 
exposure, the oxidative stress is increased [18]. Previously, it has been shown that HIF-1 and -2 levels 
are increased in HBO2 treatment due to increased ROS production [37,38]. Using a DNA microarray, 
it has been reported that more than 2% of all human genes in arterial endothelial cells are regulated 
by HIF-1α, directly or indirectly [39], including genes for vascular reactivity and structural responses. 
For example, HIF-1α affects the expression of eNOS, iNOS, HO-1, COX-2, and the production of NO 
and prostaglandin under hypoxic conditions, such as hemorrhagic shock [40]. Importantly, changes 
in partial oxygen pressure modulate the synthesis of arachidonic acid metabolites [17,41]. The 
synthesis of epoxyeicosatrienoic acids (EETs), and also of 20-hydroxysacetoxyetraenic acids, is pO2-
dependent and reaches its maximal plateau level at pO2 from 80–150 mmHg. At lower values of pO2 
the formation of 20-HETE and EETs is reduced and is linearly dependent on pO2 between 20 and 140 
mm Hg, but the slope is less steep for EETs [17]. Whether HIF-1α has a role in changes of AA 
metabolite production in hyperbaric oxygenation [41] is still unclear, since there are contradictory 
results regarding HIF-1α expression in conditions of increased pO2, with various protocols of HBO2 
exposure [42–45]. However, in our functional experiments on aortic rings, we demonstrated the role 
of HIF-1α in the restored HIR. The blockade of HIF-1α expression attenuated HIR. 
As already explained, the results of this study support our earlier hypothesis on the occurrence 
of pseudohypoxic conditions in pauses between two exposures. Although COX-1 and -2 gene 
expression decreased in the 24H-HBO2 and 4D-HBO2 groups, the protein expression of COX-2 (Figure 
5b) was increased, in accordance with the results of Kaidi et al. [46], who demonstrated that the 
upregulation of COX-2 is transcriptional and is associated with induction by HIF-1α. Results also 
indicate the association of HBO2, hypoxia, HIF-1α and increased EET production. Such results are 
consistent with the findings of Chen and Goldstein [47], suggesting a positive feedback mechanism 
that can explain induction and activation of CYP2C during hypoxia, although it remains unclear how 
EETs increase the expression of HIF-1α proteins and how phosphorylated AMPK activates 
transcription of the CYP2C gene. Suzuki and colleagues [39] have shown that the expression of 
mRNA HIF-1α does not increase with EETs and suggest that EETs stabilize HIF-1α by activating the 
PI3K/Akt path to induce the expression of VEGF. Taken together, the results of the present study 
suggest that improved relaxation in pseudohypoxic conditions after HBO2 (after one exposure or four 
days of exposures) are in line with these studies. Functional results in the present study show the 
involvement of EETs in relaxation itself. It is plausible that HBO2, by increasing tissue pO2, induces 
oxidative stress. This oxidative stress consequently activates HIF-1α, as well as CYP2C11, which is 
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followed by increased EET synthesis, which stabilizes HIF-1α. This further activates COX-2, to 
produce more prostacyclin and thus improve relaxation. Additionally, increased production of EETs 
or corresponding DiHETs serves as a substrate to increase COX activity. Once formed, 
epoxyeicosatrienoic acids (EETs) and 20-hydroxyeicosatetraenoic acid (HETE) are metabolized by β-
oxidation to 18- and 16-carbon derivatives, which are less biologically active [48–50]. 5,6-EET, 8,9-
EET and 20-HETE can also be metabolized by cyclooxygenase (COX) to vasoconstrictor 
endoperoxides or to vasodilator prostaglandin or prostacyclin-like derivatives [51]. Altogether, we 
have confirmed our hypothesis regarding the involvement of HIF-1α in HBO2 effects. The importance 
of the present study is that results are highly conclusive in terms of the contribution of the metabolites 
of arachidonic acid (produced via CYP450 pathways) in the altered mechanisms of vasorelaxation. 
The present study demonstrates the importance of EETs and 20-HETE in vasorelaxation in healthy 
experimental animals, although we have also previously demonstrated their role in conditions such 
as stroke [52,53]. The present study lays the groundwork for the transition to human studies 
considering the mechanisms of the beneficial effects of HBO2 in stroke. 
4. Materials and Methods 
4.1. Hyperbaric Oxygenation Exposure Protocols 
The animals were bred and housed at the animal care facility of the Faculty of Medicine, Osijek. 
All experimental procedures conformed to the European Convention for the Protection of Vertebrate 
Animals Used for Experimental and other Scientific Purposes (Council of Europe No 123, Strasbourg 
1985) and the European Guidelines for the Care and Use of Laboratory Animals (directive 86/609) 
and were approved by the local and national Ethical Committee (#2158/61-02-139/2-06). 
A total of 252 male Sprague-Dawley (SD) rats (aged 9–12 weeks) were used in this study. Rats 
were housed at a temperature of 21 °C–23 °C), in a humidity- and light-controlled room with free 
access to tap water and were fed ad libitum with a commercially prepared pellet diet (Mucedola, 
Italy). Hyperbaric groups underwent 120 min daily sessions of 100% O2 at 2.0 bars absolute pressure 
at a flow rate of 2–3 L/min, with an additional 15 min for gradual compression and decompression 
in a Recompression Chamber for Experiments (110L, Djuro Djakovic, Aparati d.d., Slavonski Brod, 
Croatia). A-HBO2 and 24H-HBO2 groups underwent a single session and tissue sampling was 
performed immediately after decompression or 24 h after the single exposure, respectively. Animals 
from the 4D-HBO2 group underwent one daily session for four consecutive days (intermittent) and 
tissue sampling was performed on the 5th day 24 h after the last exposure. 
4.2. Measurement of Blood Pressure 
Blood pressure measurement was performed using established protocols, as previously 
described [18,29,54,55]. Briefly, pressure values were measured using the Spacelabs Medical system 
(Spacelabs Medical, Inc., Redmond, WA, USA) using the PE-50 catheter inserted into the left femoral 
artery. The mean arterial pressure was calculated from the obtained values as a sum of systolic and 
double diastolic pressure and divided by three. As control values, the values measured in A-HBO2 
animals taken immediately prior to exposure to hyperbaric oxygenation were used. The same animals 
were used to collect thoracic aorta tissue for further analysis, including real-time quantitative PCR 
(RT qPCR) and/or protein expression by the Western blot method. Immediately after isolation, the 
aorta was transferred to a Petri dish with cold saline, cleansed from connective and fatty tissue and 
frozen in liquid nitrogen and then stored at −80 °C until analysis. 
4.3. Experiments on Isolated Aortic Rings 
The isolated aortic ring experiments were performed according to the well-established protocol 
in our laboratory [7–9,18]. After anaesthesia with ketamine 75 mg kg−1 and midazolam 0.5 mg kg−1, 
thoracotomy was made and the thoracic aorta was isolated, cut to a 3–4 mm ring width and then 
placed in an organic pool (10 mL volume) with Krebs–Henseleit’s solution (solution composition in 
mmol L−1: 120 NaCl, 4.8 KCl, 1.2 KH2PO4, 2.5 CaCl2, 1.2 MgSO4, 25.5 NaHCO3, 10 glucose and 0.02 
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EDTA) continuously heated and oxygenated (t = 37 °C, pH = 7.4). After rinsing and stabilization for 
an hour, the endothelial preservation and maximum contraction tests were done, followed by 
protocols of acetylcholine-mediated relaxation or hypoxia-mediated protocols, with or without 
inhibitors. 
4.3.1. Acetylcholine-Mediated Relaxation (AChIR) 
Following endothelial preservation of the aortic rings and a maximal precontraction test, there 
was a period of stabilization with noradrenaline (NA 10−7 mol L−1) precontraction and ACh relaxation 
at concentrations of 10−9 mol L−1 to 10−5 mol L−1, to check NO production and a baseline response to 
acetylcholine. Acetylcholine-induced relaxation of the aortic rings was measured in the absence and 
presence of (a) an NO synthase (NOS) inhibitor, Nω-nitro-L-arginine methyl ester (L-NAME, 300 
μmol L−1), (b) a cyclooxygenase inhibitor, indomethacin (INDO, 10 μmol L−1) and (c) a selective 
CYP450 epoxidase inhibitor, MS-PPOH (10 μmol L−1). 
4.3.2. Hypoxia-Induced Relaxation (HIR) 
After checking the endothelial function and stabilization, the aortic rings were precontracted 
with norepinephrine (10−7 mol L−1). Then the Krebs solution oxygenation was replaced by 95% O2 + 
5% CO2 at 0% O2 and 5% CO2 for 20 min and then switched back to 95 % O2 + 5% CO2 over 5 min for 
re-oxygenation. Thereafter, it was washed three times every 2 min followed by 10 min of stabilization 
and was then incubated with the target inhibitor for 20 min, followed by repeating the hypoxia 
protocol. The same inhibitors, as well as the acetylcholine-induced relaxation tests, were used in 
hypoxia-induced vasodilation reactions of aortic rings (L-NAME, (300 μmol L−1), INDO (10 μmol L−1) 
and MS-PPOH (10 μmol L−1)). Additionally, LW6 transcriptional HIF-1α factor inhibitor was used 
(HIF-1α inhibitor, 10 mg, Calbiochem, 10−4 mol L−1). 
4.4. Relative Gene Expression Determined by RT-qPCR Method 
The relative expression of genes relevant to the studied mechanisms was determined by real-
time quantitative PCR (RT-qtPCR; real time PCR, Bio Rad CFX96). Homogenization of the sample 
and total RNA was extracted with TRI reagent (Life Technologies, USA) according to the protocols 
of Chomczynski et al [56]. RNA concentration and sample purity were determined using a 
Nanophotometer P300 UV / VIS, IMPLEN, and confirmation of the RNA presence was performed by 
placing samples on 1% agarose gel. Sample purification and cDNA preparation were performed 
according to the manufacturer's instructions from Sigma-Aldrich and Applied Biosystems. 
Expression of following genes was determined: HIF-1α (primer sequence: forward 5’-
GCCCAGTGAGAAAGGGGAAA-3’ and reverse 5’-CGGCTGGTTACTGCTGGTAT-3’), 
cyclooxygenase 1 (COX-1, primer sequence: forward 5’-TCCTGTTCCGAGCCCAGTT-3’ and reverse 
5’-GCCAGTGATAGAGGTGGTTGAAT-3’); cyclooxygenase 2 (COX-2, primer sequence: forward 5’-
GAAAGAAATGGCTGCAGAGTTGA-3’ and reverse 5’-GCAGGGCGGGATACAGTTC-3’), vascular 
endothelial growth factor (VEGF, primer sequence: forward 5’-CGACAGAAGGGGAGCAGAAA-3’ 
and reverse 5’-GCTGGCTTTGGTGAGGTTTG-3’), inducible nitric oxide synthase (iNOS; NOS2, 
primer sequence: forward 5’-TGGTGAGGGGACTGGACTTT-3’ and reverse 5’-
CCAACTCTGCTGTTCTCCGT-3’), endothelial nitric oxide synthase (eNOS; NOS3, primer sequence: 
forward 5’-CGAACAGCAGGAGCTAGAGG-3’ and reverse 5’-GAGGTGGATCTCTCCTGGGT-3’) 
and CYP2c11 (primer sequence: forward 5’-CAATCCGCAGTCTGAGTT-3’, reverse 5’-
TGCTGAGAATGGCATAAA-3’). Relative expression (Table 2) of a particular gene was quantified in 
relation to the expression of the hypoxanthine-guanine phosphoribosyl transferase (HPRT, primer 
sequence: forward 5’-GAAAGAACGTCTTGATTGTTGAAGATAT-3’ and reverse 5’-
GAGAGGTCCTTTTCACCAGCAA-3’). 2−ΔΔCt calculation was performed using the Livak and 
Schmittgen method [57] and presented as fold change for mRNA expressions normalized to 
housekeeping gene and control (Figure 4). 
4.5. Relative Protein Expression Determined by Western Blot 
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The Western blot was made according to the established method of our laboratory [9,55]. The 
same Western blot protocol was used to determine the COX-1, COX-2, iNOS, HIF-1α, VEGF and 
CYP2c11 protein expression in the rat aortas, deeply frozen immediately after isolation. For 
homogenization of the tissue the homogenization buffer (1 mmol L−1 EDTA, 10 mmol L−1 Tris (Fisher 
Scientific, Belgium), 0.4% SDS (Acros Organics, USA), cocktail inhibitor protease 0.4 μL/100 μL 
(Sigma Aldrich, USA)) was used, with addition of 1 mmol L−1 cobalt chloride. The frozen tissue was 
pulverized in liquid nitrogen, weighed and 1 mL of the homogenization buffer was added to 100 mg 
of tissue. Everything was well-vortexed and centrifuged (15,000× g, 30 min, 4 °C) and supernatant 
was used for further analysis. Before loading on gels, samples were cooked for 5 min in 1:1 ratio with 
Laemmli sample buffer (2× Laemmli Sample Buffer, Bio-Rad, USA, #161-0737), with the addition of 
β-mercaptoethanol as a reducing agent. After SDS-PAGE electrophoresis (100V const., approximately 
2 h), the samples were transferred to the PVDF (200 mA const., 2 h) membrane, blocked (5% non-fat 
milk, 1 h, room temperature) and then incubated with the primary antibody (COX-1 rabbit PolyAB, 
Proteintech Europe, UK, #13393-1-AP, 1:500; COX-2 rabbit PolyAB, Proteintech Europe, UK, #12375-
1-AP, 1:500; iNOS rabbit PolyAB, Proteintech Europe, UK, #18985-1-AP, 1:1000; HIF-1α rabbit 
PolyAB, Thermo Scientific, USA, PAI-16601, 1:1000; VEGF rabbit PolyAB, Proteintech Europe, UK, 
#19003-1-AP, 1:500; CYP2C11 mouse monoclonal AB, Detroit R&D, USA, #P2C11PT, 1:2000) 
overnight at 4 C. The next day, the membrane was incubated with appropriate horse radish 
peroxidase (HRP)-labeled secondary antibody (goat anti-rabbit HRP, Abcam, UK, ab205718; goat 
anti-mouse HRP, Santa Cruz Biotechnology, USA, sc-2005, both in 1:7500 dilution) for 2 h at room 
temperature and was subsequently photographed by a chemiluminescence method using the Pierce 
ECL Western Blotting Substrate (Thermo Scientific, USA) according to the manufacturer’s 
instructions, on the Bio-Rad ChemiDoc Imager. As a control of the sample application and for 
normalization, expression of β-actin (mouse monoclonal antibody, Santa Cruz Biotechnology, USA 
sc-47778, 1:7500) was determined.  
4.6. Determination of CYP450 Enzymatic Pathway Metabolites of Arachidonic Acid  
To determine CYP450 enzymatic pathway metabolites of arachidonic acid in aorta samples, 
liquid chromatography-tandem mass spectrometry was used [58–61]. 
Sample Preparation 
Blood vessels were placed in to Precellys vials (2 mL), and 1 mL methanol with internal standard 
(IS) was added (concentration of IS was 50 ng mL−1). The samples were homogenized for 2 × 15 sec at 
4500 rpm and the next 20 s at 6000 rpm in a Precellys Evolution tissue homogenizer (Bertin 
Technologies, Montigny-le-Bretonneux, France). After homogenization, the samples were 
centrifuged for 5 min at 10,000 rpm in Thermo SL 40R centrifuge (Thermo Fisher Scientific, Waltham, 
MA, USA). The supernatants were moved to 1.4 mL polypropylene tubes and 200 μL of DMSO were 
added. The solvent was completely removed by means of a Biotage SPE DRY 96 sample evaporation 
system (Biotage AB, Uppsala, Sweden)[62]. 
Prior to analyses, the samples were reconstituted in a mixture of acetonitrile and water (v/v, 1:1), 
centrifuged and separated in analytical plates (LCMS PLATES: Agilent 96-well plates 0.5 mL 
polypropylene P/N 5042-1385, J.G. Finneran PTFE 96-Well Pattern Sealing Film, Patented P/N BST-
9790). 
Standards for calibration curve preparation: arachidonic acid (Sigma-Aldrich, from non-animal 
source, ≥98.5% (GC)) was dissolved in DMSO (10.0 mg mL−1) and diluted in methanol to 100 μg mL−1. 
The Arachidonic Acid CYP450 Metabolite LC-MS Mixture (Cayman Chemicals Company, Ann 
Arbor, MI, USA) Arachidonic Acid CYP450 Metabolite LC-MS Mixture, Item No. 20665, declared to 
contain 10 μg mL−1 of each compound) was diluted in methanol to 100 μg mL−1 (Table 5). The 
calibration range was from 0.001 to 50 ng mL−1 for all of standards except for the arachidonic acid, for 
which it was from 0.001 to 50 μg mL−1. The calibration points were 0.001, 0.005, 0.01, 0.05, 0.1, 0.5, 1, 
5, 10 and 50 ng mL−1 (μg mL−1 for arachidonic acid, respectively). Quantification was performed by 
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summing the three MRM signals of the same transition (differing for 0.001 Da) for each analyte in 
order to increase sensitivity. 
Table 5. List of standards used for liquid chromatography-tandem mass spectrometry. 
Analyte Units RT (min) MRM Transition 
14(15)-DiHET ng mL−1 7.09 337.100/207.100 Da 
11(12)-DiHET ng mL−1 7.50 337.100/167.100 Da 
8(9)-DiHET ng mL−1 7.87 337.100/185.100 Da 
19-HETE ng mL−1 8.10 319.095/231.300 Da 
20-HETE  ng mL−1 8.27 319.095/245.300 Da 
5(6)-DiHET ng mL−1 8.39 337.100/145.100 Da 
14(15)-EET ng mL−1 10.8 319.143/219.100 Da 
11(12)-EET ng mL−1 11.4 319.113/167.100 Da 
8(9)-EET ng mL−1 11.6 319.113/127.100 Da 
AA g mL−1 14.5 303.300/259.300 Da 
HPLC-electrospray ionization (ESI)/MS-MS: chromatographic separation was performed with a 
Waters Acquity UPLC® BEH C18 column (2.1 × 50 mm; 1.7 μm particle size) (Waters, USA) and a 
gradient elution of mobile phase A (0.1% formic acid in water) and phase B (acetonitrile, at a flow 
rate of 400 μL min−1), according to the previously described method, modified as follows [63]. The 
acetonitrile part was 25% (v/v) at first, increasing to 50% within 7.5 min. The percentage of acetonitrile 
was continuously increased. At 12.5 min it was 60 percent and at 16 min it was 90 percent. It was held 
at 90% for a further 2 min. At 18.01 min the percentage of acetonitrile was reduced to 25 percent and 
was maintained at that level for 20 min. The column was reconditioned for 15 min with 75% of 0.1% 
formic acid in water and 25% acetonitrile (Table 6). Column temperature was 50 °C and autosampler 
temperature was 4 °C. 
Table 6. Gradient table for chromatographic separation (Mobile phase A: 0.1% formic acid in water; 
mobile phase B: acetonitrile, %B–percentage of acetonitrile as mobile phase). 








All measurements were carried out with a Shimadzu Nexera X2 HPLC system coupled to an AB 
Sciex QTRAP 6500 ion trap mass spectrometer from AB SCIEX (Framingham, MA, USA), operated 
under negative-ion electrospray (ESI) conditions in the SIM (Single (Selected) Ion Monitoring) and 
MRM (Multiple Reaction Monitoring) modes, respectively. Representative liquid chromatography-
tandem mass spectrometry chromatograms are presented in Figure 6. 
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Figure 6. Representative liquid chromatography-tandem mass spectrometry chromatograms 
illustrating the profile of epoxyeicosatrienoic acid (EET) and HETEs formed by rat cerebral arteries, 
obtained under described experimental conditions. 
4.7. Statistical Analysis 
All results are expressed as average ± standard deviation (SD). p < 0.05 was considered 
statistically significant. Acetylcholine-induced relaxation is expressed as a percentage of the 
maximum contraction. The response to ACh was analyzed via a two-way ANOVA with a post hoc 
Bonferoni test. For a comparison of mRNA and protein expression results and hypoxia-mediated 
relaxation of aortic rings, a one-way ANOVA variance test was used, or in the case of unequal 
distribution, Holm–Sidak or Kruskal–Wallis test data were obtained. For individual results, the 
determination of the difference between the normal distribution of numeric variables between the 
two independent groups was performed using Student’s t-test, and in the case of a deviation from 
the normal distribution, the Mann–Whitney U test was used. SigmaPlot v.12 (Systat Software, Inc., 
Chicago, USA) and GraphPadPrism, Version 5.00 for Windows, GrafPad Software (San Diego, CA, 
USA) were used for statistical analysis. 
5. Conclusions 
In conclusion, intermittent HBO2 exposure causes enhanced relaxation, most likely by activating 
the CYP450 epoxygenases pathway of arachidonic acid metabolism and by increasing the formation 
of and sensitivity to EETs. In addition, HBO2 increases the expression of HIF-1α, which stimulates 
COX pathway expression and prostacyclin formation, thereby mediating enhanced relaxation in 
intermittent HBO2 exposure. 
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CYP450 Cytochrome P450 
HIF-1α Hypoxia inducible factor 1 alpha 
AChIR Acetylcholine-induced relaxation 
HIR Hypoxia-induced relaxation 
HBO2 Hyperbaric oxygen 
EET Epoxyeicosatrienoic acid 
HETE Hydroxyeicosatetraenoic acid 
COX-1 Cyclooxygenase 1 
COX-2 Cyclooxygenase 2 
AA Arachidonic acid 
LC-MS/MS Liquid chromatography-tandem mass spectrometry 
NO Nitric oxide 
ANGII/ANG(1-7) Angiotensin II/Angiotensin (1-7)  
PGI2 Prostacyclin 
cAMP Cyclic adenosine monophosphate 
ROS Reactive oxygen species 
RNS Reactive nitrogen species 
MS-PPOH N-(methyl sulfonyl)-2-(2-propynyloxy)-benzenehexanamide 
INDO Indomethacin 
L-NAME Nω-nitro-L-arginine methyl ester 
iNOS Inducible nitric oxide synthase 
eNOS Endothelial nitric oxide synthase 
VEGF Vascular endothelial growth factor 
mRNA Messenger ribonucleic acid 
EDHFs Endothelium-derived hyperpolarizing factors 
ACh Acetylcholine 
SD Sprague-Dawley rats 
RT qPCR Quantitative reverse transcription polymerase chain reaction 
EDTA Ethylenediaminetetraacetic acid 
RNA Ribonucleic acid 
HPRT Hypoxanthine-guanine phosphoribosyl transferase 
SIM Single (Selected) Ion Monitoring 
MRM Multiple Reaction Monitoring 
SDS Sodium dodecyl sulfate 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
DMSO Dimethyl sulfoxide 
HPLC-ESI/MS-
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